Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma.

Oncogene·2026
Same author

Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.

Oncogene·2022
Same author

A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis.

eLife·2016
Same author

COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats.

The Journal of surgical research·2009
Same author

Mass spectral characterization of organophosphate-labeled, tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2009
Same author

3D-SURFER: software for high-throughput protein surface comparison and analysis.

Bioinformatics (Oxford, England)·2009

関連する実験動画

Updated: May 3, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

肝細胞がんにおけるバイカルボネート統合経動脈化学栓塞 (TACE)

Kai Jin1, Siying Zeng2,3, Bin Li1

  • 1Interventional Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Signal transduction and targeted therapy
|August 31, 2025
PubMed
まとめ

TILA- TACEは,肝細胞がん (HCC) の局所的な制御において,99%の客観的な応答率を提供し,従来の治療法に比べて有意に改善しています. この新しい治療法は,特にHCCの進行段階では,許容可能な安全性プロファイルと生存効果を示しています.

さらに関連する動画

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

596

関連する実験動画

Last Updated: May 3, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

596

科学分野:

  • 肝胆腫瘍学
  • 介入放射線学
  • 放射線腫瘍学

背景:

  • 肝細胞癌 (HCC) の従来型のトランス動脈性化学栓塞 (TACE) は,局所的対照群で約50%の客観的な応答率を示しています.
  • TILA- TACEは以前,切除できないHCCの局所的制御において100%の有効性を示しました.

研究 の 目的:

  • HCCの治療におけるTILA- TACEの有効性,選択性,安全性を検証する.
  • 肝臓外転症を含む高度なHCCに対する放射線療法と併用したTILA- TACEのアウトカムを評価する.

主な方法:

  • この実用的な検証研究では,HCC (初期,中期,および進行段階) の合計413人の患者が登録されました.
  • TILA- TACEは原発性腫瘍の治療に使用され,放射線療法はマクロ血管侵入および肝臓外転移の治療に使用された.
  • TILA- TACEの副作用は体系的に記録され,分析されました.

主要な成果:

  • TILA- TACEはHCC腫瘍の99. 01%の客観的な応答率を達成し,完全な応答率は72. 77%であった.
  • 放射線療法は96. 88%の腫瘍血栓に対する客観的な応答率を示した.
  • 進行したHCC患者の生存期間の中央値は27ヶ月で,肝臓内転移ががん関連死亡の主な原因でした.

結論:

  • TILA- TACEは,HCCの局所的な制御のための非常に有効で安全な新しい治療法であり,許容可能な安全性プロファイルを持っています.
  • TILA- TACEと放射線療法の組み合わせは,進行したHCC患者の生存に顕著な利点をもたらします.
  • 肝臓内転移を治療後の死亡の原因として扱うためのさらなる研究が必要である.